Objective,2,To select out the optimal compatibility of Jiangzhi Granule components for improving non-alcoholic fatty liver disease (NAFLD).,Methods,2,①HepG2 and L02 cells were induced by fatty acids for 24 hours to establish a model of hepatosteatosis (model group, M).Six compatibility groups (named A, B, C, D, E, F) combined by 3 major components of Jiangzhi Granule (including protopanaxadiol, tanshinoneⅡA and emodin) according to the weighed modification method were used to intervene the model cells for 24 h. Cells cultured in the normal medium were used as normal control. The optimal proportion group was selected according to the effect of drugs on alleviating lipid accumulation observed by oil red O staining and intracellular triglyceride (TG) 、total cholesterol (TC) content. The effect of the optimal group was also compared with the individual effect of the three active components.②SPF male C57BL/6J mice were randomly divided into normal group, model group, compatible F high-dose group and compatible F low-dose group according to their body weight, with 8 mice in each group. The mice in the normal group was fed with ordinary feed, and the rest were given high-fat feed. After 22 weeks of inducting NAFLD modeling, the mice were treated with corresponding drugs for 8 weeks. The body weight, liver weight, serum alanine aminotransferase (ALT), serum lipid and hepatic histopathological changes were detected to verify the efficacy of the optimal compatibility.,Results,2,①Cell oil red O staining showed that a large number of lipid droplets accumulated in the cells of the model group, which were alleviated in different degrees in all of the 6 compatibility groups. The detection of cellular TG content showed that the TG content in the group M increased, while the level of TG decreased significantly in the group C and the group F, among which group F had the most significant effect. Moreover, the effect of group F on reducing lipid accumulation was better than protopanaxadiol, tanshinone ⅡA and emodin alone. ②The body weight, liver weight and serum ALT of NAFLD mice in model group were significantly higher than those in the control group, and the intervention of compatible F high-dose group could significantly reduce the level of liver weight and ALT. Both compatible F high-dose group and compatible F low-dose group could reduce the level of serum TC in NAFLD mice, and compatible F high-dose group could significantly down-regulate the levels of high density lipoprotein cholesterol (HDL-c) and low density lipoprotein cholesterol (LDL-c). HE staining and oil red O staining showed that compatible F high-dose group and compatible F low-dose group improved hepatocyte steatosis in a dose-dependent manner.,Conclusion,2,Through the experiment ,in vivo, and ,in vitro, the drug compatibility group F composed of propanaxadiol, tanshinone ⅡA and emodin is selected out, which can improve serum lipid, hepatosteatosis and liver function of NAFLD model and helps to establish the experimental basis for the development of new type of drugs for NAFLD with controllable quality and stable therapeutic effects.